Table 2.

Some neutralizing antiviral antibodies in clinical trials

Antibody	Target	Indication	Company	Clinical phase	ClinicalTrials.gov Identifier
Ibalizumab	CD4	HIV infection	TaiMed Biologics USA Corp	Approved	NCT02707861 NCT02716675 NCT02568215
VRC01, NIAID	CD4- of HIV gp120	HIV infection	NIAID Vaccine Research Centre (VRC)	2	NCT02664415 NCT02588586 NCT02850016
3BNC117	CD4- HIV-1 Env protein.	HIV infection	Rockefeller University	2	NCT02446847 NCT02511990 NCT02825797
10–1074	V3-glycan supersite of HIV gp120	HIV infection	Rockefeller University	1	NCT02825797
4E10,2F5, 2G12	gp41	HIV infection	Rockefeller University	1/2	NCT00219986
PRO 140	CCR5 receptors	HIV infection	CytoDyn, Inc	2b/3	NCT01272258
ZMapp		Ebla infection	Public Health Agency of Canada, Defyrus	2/3	NCT02389192
MHAA4549A (39.29)	Hemagglutinin influenza A	influenza A infection	Genentech, Inc	2	NCT02623322
VIS410	Hemagglutinin (HA)	influenza A infection	Visterra, Inc	2	NCT02989194
CR6261	HA1/HA2 from 1918 H1N1 influenza and H5N1	influenza infection	National Institute of Allergy and Infectious Diseases (NIAID	2	NCT02371668
CR8020	Hemagglutinin (HA)	influenza A infection	Crucell Holland B. V	2	NCT01938352
TCN-032	the ectodomain of influenza A	influenza A infection	Theraclone Sciences	2	NCT01719874